FIELD: medicine, pharmacology.
SUBSTANCE: invention relates to method for assay of optimized regimens in dosing erythropoietin (EOR). Invention proposes a system for election of one or some regimens in dosing by using pharmacokinetic/pharmacodynamic (PK/PD) as a model for assay of PK/PD pattern regimens. Then method involves selection of such regimen that provides the serum concentration of EOR exceeding its before administration for 5-30 days between administrations of EOR. Invention provides optimal applying EOR for correction of blood indices changes and treatment of diseases associated with them.
EFFECT: improved and valuable modeling method.
50 cl, 81 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC WAYS FOR TREATING PATIENTS WITH RECOMBINANT ERYTHROPOIETIN OF HIGH ACTIVITY AND DECREASED SIDE EFFECTS | 2001 |
|
RU2282460C2 |
| PHARMACEUTICAL COMPOSITIONS OF ERYTHROPOIETIN | 2000 |
|
RU2225221C2 |
| METHOD OF TREATING ANEMIA WITH USE OF ERO COMPOSITION OF LONG-TERM EFFECT | 2016 |
|
RU2673548C1 |
| COMPOSITIONS OF LONG-ACTING INSULIN | 2011 |
|
RU2564104C2 |
| HYBRID PROTEIN BASED ON RECOMBINANT HUMAN ERYTHROPOIETIN, HAVING PROLONGED ACTION (VERSIONS), AND METHOD OF ITS PRODUCTION | 2013 |
|
RU2515914C1 |
| COMPOSITIONS OF LONG-TERM ACTION INSULINS | 2015 |
|
RU2642662C2 |
| COMPOSITIONS AND METHODS OF TREATING ANAEMIA | 2014 |
|
RU2705206C2 |
| RECOMBINANT FUSED HUMAN PROTEIN EPO-FC WITH PROLONGED TIME OF HALF-LIFE AND INCREASED ERYTHROPOETIC ACTIVITY IN VIVO (VERSIONS), DIMERIC PROTEIN CONSTRUCTION, DIMERIC PROTEIN, PHARMACEUTICAL COMPOSITION, SEQUENCE OF NUCLEIC ACID (VERSIONS), EXPRESSION VECTOR, CELL, METHOD OF OBTAINING PROTEIN AND METHOD OF ERYTHROPOESIS STIMULATION IN MAMMAL | 2007 |
|
RU2433181C2 |
| APPLICATION OF STABILISERS OF HIF- ALPHA FOR INTENSIFICATION OF ERYTHROPOIESIS | 2004 |
|
RU2414214C2 |
| ERYTHROPOIETIN APPLICATION FOR POSTINSULT REHABILITATION | 2004 |
|
RU2341284C2 |
